Highlights from APCCC 2026

ASCO 2026: Updates in bladder cancer

ASCO 2026: Updates in testicular, germ cell and rare genitourinary cancer

Favezelimab plus pembrolizumab improves progression-free survival in PD-1-refractory classic Hodgkin lymphoma

ASCO 2026: Comment: Multi-cancer earlier detection tests

Velzatinib demonstrates broad activity across KIT mutations in advanced gastrointestinal stromal tumours

miR371 shows promise as a surveillance biomarker for relapse in early-stage germ cell tumours

Challenges in high-risk NMIBC: Addressing current unmet needs to optimise patient care

Current state of cancer genomics in Africa

Exploring genetic essentiality and drug sensitivity in triple-negative breast cancer

Improving African representation in breast cancer genomics

Integrating oncogenetics testing into African clinics and cancer control programs